drugset / Trial / NCT04662632

Abbreviated Protocol for Two-Stage Exchange

NCT04662632

Phase 2 Completed 76 enrolled Osteal Therapeutics, Inc.
RandomizedParallel-groupSingle-blindTreatment

Summary

Study Type: A multi-site, parallel group, randomized trial. Study Objectives: The objective is to evaluate safety and determine preliminary efficacy of VT-X7 (Vancomycin and Tobramycin Exchanged over 7 Days). Efficacy is evaluated as superiority of the Experimental Arm in a composite endpoint of Overall Success at 90 days, consisting of a revision prosthesis implanted at Stage 2, patient survival, absence of reoperation and absence of periprosthetic joint infection (PJI). Secondary objectives are to evaluate superiority at 365 days in a composite endpoint of Overall Success, and in separate secondary endpoints for quality of life and patient survival. The exploratory objective is to compare Experimental and Control Arms in exploratory endpoints. Follow-up: Patients will be evaluated at 90-, 180-, and 365-day follow-up visits.

Timeline

Start
2021-11-01
Primary completion
2023-03-13
Completion
2023-12-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Tobramycin Small molecule 80 mg Other
Subject Vancomycin Other / unclassified 125 mg Other